Rapid review

In some cases, there is not enough time to prepare a full HTA report. At the same time, if a well-established drug or an innovative, new technology is considered, it is completely reliable to determine efficacy and safety of the technology by means of a rapid review. In the case of well-established drug, the analysis of efficacy and safety can be based on the results of credible secondary studies. In the case of new technologies, it often occurs that there are only few studies of high quality and that the properly conducted systematic review will indicate only few publications, which subsequently will be included as a basis for the analysis.